INDEMNITY AGREEMENTIndemnity Agreement • February 5th, 2024 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations • Delaware
This Indemnity Agreement (this “Agreement”), effective as of ___________, is made by and between NeOnc Technologies Holdings, Inc., a Delaware corporation with executive offices located at 2 Dole Drive, Westlake Village, California 91362 (the “Company”), and, __________________ of the Company residing at __________________ (the “Indemnitee”).
NEONC TECHNOLOGIES HOLDINGS, INC. AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENTRestricted Stock Award Agreement • February 23rd, 2024 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations • Delaware
NeOnc Technologies Holdings, Inc., a Delaware corporation (“Company”), hereby grants an Award of Restricted Stock, subject to the terms, conditions, and restrictions of the Company’s 2023 Equity Incentive Plan (the “Plan”), and this Restricted Stock Award Agreement, including Appendix A attached hereto (the Restricted Stock Award Agreement and Appendix A are collectively referred to as the “Award Agreement”). This Award Agreement amends and restates that certain Award Agreement dated January 4, 2024 between the Company and Grantee. The capitalized terms used in the Award Agreement but not defined herein shall have the meanings set forth in the Plan.
EMPLOYMENT AGREEMENTEmployment Agreement • January 16th, 2024 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is entered into as of the 4th day of January, 2024, by and between NeOnc Technologies Holdings, Inc., a Delaware corporation (the “Company”), and Patrick Walters, an individual residing at the address set forth on Schedule A hereto (the “Executive”).
LEASE AGREEMENTLease Agreement • February 5th, 2024 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations • California
THIS LEASE AGREEMENT (the “Lease”) is made and entered into as of the 1st day of February, 2024, by and between WESTLAKE WELLBEING PROPERTIES, LLC, a Delaware limited liability company (“Landlord”), and NEONC TECHNOLOGIES HOLDINGS, INC., a Delaware corporation (“Tenant”).
CONFIDENTIAL October 16, 2023 Dr. Thomas Chen, M.D., Ph.D. Chief Executive Officer & Chief Scientific Officer NeOnc Technologies Holdings, Inc. Los Angeles, CA 90069Neonc Technologies Holdings, Inc. • December 18th, 2023 • Pharmaceutical preparations • New York
This letter confirms our agreement that NeOnc Technology Holdings, Inc. (the “Company”) is hereby engaging Maxim Group LLC (together with its affiliates and subsidiaries, “Maxim”) to act as the Company’s non-exclusive advisor whereby Maxim has already rendered and may render certain additional advisory services to the Company, as enumerated in Section 1 below.
NEONC TECHNOLOGIES HOLDINGS, INC. 2023 EQUITY INCENTIVE PLAN OPTION EXERCISE AGREEMENTOption Exercise Agreement • December 18th, 2023 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations • Delaware
This OPTION EXERCISE AGREEMENT (this “Agreement”) is made as of ____________, by and between NeOnc Technologies Holdings, Inc., a Delaware Corporation (the “Company”), and ___________________ (“Purchaser”). To the extent any capitalized terms used in this Agreement are not defined, they shall have the meaning ascribed to them in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive Plan (the “Plan”) and the Option Agreement (as defined below).
NEONC TECHNOLOGIES HOLDINGS, INC. RESTRICTED SHARE UNIT AWARD AGREEMENTRestricted Share Unit Award Agreement • December 18th, 2023 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations • Delaware
NeOnc Technologies Holdings, Inc., a Delaware corporation (“Company”), hereby grants an Award of Restricted Share Units, subject to the terms, conditions, and restrictions of the Company’s 2023 Equity Incentive Plan (the “Plan”), and this Restricted Share Unit Award Agreement, including Appendix A attached hereto (the Restricted Share Unit Award Agreement and Appendix A are collectively referred to as the “Award Agreement”). The capitalized terms used in the Award Agreement but not defined herein shall have the meanings set forth in the Plan.
NEONC TECHNOLOGIES HOLDINGS, INC. 2023 EQUITY INCENTIVE PLAN OPTION EXERCISE AGREEMENTOption Exercise Agreement • December 18th, 2023 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations • Delaware
This OPTION EXERCISE AGREEMENT (this “Agreement”) is made as of ____________, by and between NeOnc Technologies Holdings, Inc., a Delaware corporation (the “Company”), and ___________________ (“Purchaser”). To the extent any capitalized terms used in this Agreement are not defined, they shall have the meaning ascribed to them in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive Plan (the “Plan”) and the Option Agreement (as defined below).
FORM OF SHARE EXCHANGE AGREEMENTForm of Share Exchange Agreement • December 18th, 2023 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS SHARE EXCHANGE AGREEMENT (this “Agreement”), is made and entered into as of April 7, 2023 (the “Effective Date”) by and among NeOnc Technologies Holdings, Inc., a Delaware corporation (the “Parent”), NeOnc Technologies, Inc., a Delaware corporation (the “Company”) and the stockholders of the Company signatory hereto (the “Company Stockholders”). The Parent, the Company and the Company Stockholders are each a “Party” and referred to collectively herein as the “Parties.”
COLLABORATION AND LICENSE AGREEMENT BETWEEN ORIENT EUROPHARMA CO., LTD. AND NEONC TECHNOLOGIES, INC.Collaboration and License Agreement • December 18th, 2023 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations
COLLABORATION AND LICENSE AGREEMENT This COLLABORATION AND LICENSE AGREEMENT (“Agreement”), is entered into and effective as of ovember 8th. 2013 (the··Effective Date”), by and between NeOnc Technologies, Inc., a Delaware corporation having its principal place of business at 21700 Oxnard Street, Suite 900, Woodland Hills. California 91367. USA (“NeO.nc”), and Orient EuroPharma Co.. Ltd., a company organized and existing under the laws of Taiwan having a principal place of business at 7F, No. 368, Sec. I Fu Hsing .. Rd., Taipei I0656. Taiwan. Republic of China (‘·OEP”). NeOnc and OEP are each referred to herein by name or as a “Party” or. collectively, as the “Parties.” WHEREAS, NeOnc is the owner and licensee of certain patents, formulations, know-how, and technology related to purified perillyl alcohol as a therapeutic agent; and WHEREAS, OEP is engaged in the research, development. marketing, manufacture. and distribution of phannaceutical compounds and is interested in developing an
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 18th, 2023 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations
This Amended and Restated Exclusive License Agreement (the “Agreement”) is effective as of November 20th, 2023 (the “Effective Date”), by and between University of Southern California, a California nonprofit corporation (“USC”), and NeOnc Technologies, Inc. (f/k/a NAS-ONC), a California corporation (“Licensee”), located at the address set forth in Section 13.15 below, with respect to the facts set forth below.
NEONC TECHNOLOGIES HOLDINGS, INC. 2023 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENTStock Option Agreement • December 18th, 2023 • Neonc Technologies Holdings, Inc. • Pharmaceutical preparations • Delaware
This STOCK OPTION AGREEMENT (this “Agreement”) is by and between NeOnc Technologies Holdings, Inc., a Delaware corporation (the “Company”), and the Optionee named above (the “Optionee”). The right to purchase the number of shares of the Company’s Common Stock identified above (the “Option”) is granted pursuant to and subject to the terms and conditions set forth in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive Plan (the “Plan”). Capitalized terms used herein and not otherwise defined herein shall have the meaning assigned by the Plan.
